In the last few years, the proportion of older patients has increased sharply as a consequence of more longevity, thus resulting in big changes to the epidemiology and pathways of acute coronary syndromes (ACSs). The big picture is now characterised by a greater use of revascularisation therapy in ACS patients aged 75 years and older with reduced inhospital mortality, which is mirrored by the increased presentation of patients with serious comorbidities, chronic or post-event disability and elevated post-discharge mortality.
The longitudinal association in CVD patients between frailty and incidental mortality has only recently been figured out. Frailty is a significant predictor of all-cause mortality and hospital re-admissions in heart failure patients, with an increased risk of about 60% and 30%, respectively. 8 Moreover, it was associated with a fourfold increased risk of 30-day mortality and a twofold increased risk of long-term mortality after major vascular surgery, without differences regarding open surgery and endovascular procedures. 9 Frailty is also an independent prognostic marker of mortality and re-infarction in patients admitted due to ACSs during a follow-up of one year, 10,11 the latter being the usual time horizon of earlier observational studies.
In the current issue of the journal, Ekerstad and colleague 12 provided a follow-up after more than 5 years of elderly patients with non-ST-segment elevation myocardial infarction (NSTEMI), according to the presence of frailty. In that study the frailty condition was assessed by using the Canadian Study of Health and Aging clinical frailty scale (CFS), and was found in approximately half of the patients considered. The main message was that in elderly NSTEMI patients, frailty was independently associated with all-cause mortality at long-term follow-up; second, that the association between frailty and long-term mortality became weaker over time, while the association between comorbidity and long-term mortality became stronger.
So how should this information be used in clinical practice? Are we starting to evaluate all patients presenting with ACSs for frailty? Indeed, several questions still remain unanswered and limit a clear indication.
First, we need to identify frailty tools with a high quality of evidence, user friendly for cardiologists treating ACS patients, to be integrated into or added to other methods for cardiovascular risk estimation. Actually, the availability of several multidimensional tools (such as the FRAIL questionnaire, the CFS, the Edmonton frailty scale, the Rockwood scale, just to name a few in addition to the original Fried's criteria) might confuse and discourage clinicians -mainly during the acute phase of ACSs -who are generally more confident with thrombotic and left ventricular remodelling risk prediction. A proper definition of the good time to frailty evaluation is also important: should multi-items be related to personal history before ACS or should they be appreciated after clinical stabilisation from ACS? What might the temporal cutoff be? Low physical activity, exhaustion, and unintentional weight loss are common findings in older people after ACSs: how should we manage this 'transient frailty' in terms of cardiovascular prognosis?
Then there is a need for further action to address the problem to harmonise the evaluation of frailty with common scales and indices for disability and comorbidity. The work by Ekerstad et al. 12 tells us that it is important to match frailty and comorbidities, but how can we rationalise efforts in a context of limited human and time resources? The answer is probably that cardiologists should work together with geriatricians and other allied health professionals, to become more familiar with frailty instruments.
Above all, even though fascinated by opening the 'Pandora's box of frailty' of our patients, the matter of how this condition could guide clinical decisions and how to provide comprehensive care to reverse frailty and increase cardiovascular prognosis are still a matter of debate. Reasonably, appropriate and fasttracked referral to cardiac rehabilitation (CR) could represent a smart move. Despite the fact that the 'CR bottleneck' (i.e. all patients with ACS have an indication for CR, but only very few benefit from an adequate intervention) 13 appears to be markedly narrow for frail elderly patients, exercise-based CR programmes really represent the ideal setting to obtain improvement in physical mobility, functional capacity, fall prevention, disability prevention or decreased progression, and improvement in nutrition and quality of life.
14 As in many cases ACS could represent real 'acute frailty syndromes', it must be given due consideration that there are not only vulnerable atherosclerotic plaques, but 'vulnerable patients' and 'vulnerable care settings' too.
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